7-Methylxanthine
Based on 1 Customer Validation
7-Methylxanthine is an orally active methyl derivative of xanthine and a non-selective adenosine receptor antagonist. 7-Methylxanthine is also one of the purine components of human urinary calculi. 7-Methylxanthine has anti-myopia activity.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 552-62-5
- Formula: C6H6N4O2
- Molecular Weight:166.14
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W008449
1-Methylxanthine -
HY-W016498
Paraxanthine -
HY-50723
3-Methylxanthine -
HY-50723R
3-Methylxanthine (Standard) -
HY-W017163R
7-Methylxanthine (Standard) -
HY-B1449
Uridine -
HY-113327
1,3,7-Trimethyluric acid -
HY-B1449R
Uridine (Standard) -
HY-116887
N6-Methyladenine -
HY-116887R
N6-Methyladenine (Standard) -
HY-131818
5'-Amino-5'-deoxyadenosine -
HY-113327R
1,3,7-Trimethyluric acid (Standard)
Biological Activity
Description
IC50 & Target
|
Human Endogenous Metabolite |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Macaca mulatta aged 2-3 weeks old were reared with -3D or +3D spectacle over their treated eyes and zero-powered lenses over their fellow eyes[2]
-
Dosage:100 mg/kg
-
Administration:Oral administration, twice daily, from 24±2 days of age until 147±4 days of age
-
Result:Eliminated the consistent myopic anisometropia normally produced by -3D of imposed monocular defocus.
Caused compensating hyperopic anisometropias.
Changed the course of emmetropization in both the treated and fellow eyes of the lens-reared monkeys, resulting in more hyperopic refractive errors.
Led to a reduction in vitreous chamber elongation and an increase in choroidal thickness.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 552-62-5
-
Appearance Solid
-
Molecular Weight 166.14
-
Formula C6H6N4O2
-
Color White to light brown
-
SMILES
CN1C=NC2=C1C(=O)NC(=O)N2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
In Vitro:
DMSO : 3.33 mg/mL (20.04 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 8.33 mg/mL (50.14 mM); Suspended solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Caubet MS, et al. Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity. J Pharm Biomed Anal. 2004 Feb 4;34(2):379-89. [Content Brief]
[2]. Hung LF, et al. The Adenosine Receptor Antagonist, 7-Methylxanthine, Alters Emmetropizing Responses in Infant Macaques. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):472-486. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.0190 mL | 30.0951 mL | 60.1902 mL | 150.4755 mL |
| 5 mM | 1.2038 mL | 6.0190 mL | 12.0380 mL | 30.0951 mL | |
| 10 mM | 0.6019 mL | 3.0095 mL | 6.0190 mL | 15.0476 mL | |
| 15 mM | 0.4013 mL | 2.0063 mL | 4.0127 mL | 10.0317 mL | |
| 20 mM | 0.3010 mL | 1.5048 mL | 3.0095 mL | 7.5238 mL |
7-Methylxanthine Related Classifications
HY-W017163 Related Classifications
Powered by Bioz